The role of radiation in retroperitoneal sarcomas
- PMID: 23649911
- PMCID: PMC3769487
- DOI: 10.1007/s11864-013-0236-6
The role of radiation in retroperitoneal sarcomas
Abstract
Retroperitoneal sarcomas form a group of rare malignancies that require expertise in every aspect of management. Patients benefit from referral to cancer centers that can provide comprehensive, multidisciplinary, oncologic management. The role of radiation in retroperitoneal sarcoma management is, appropriately, the subject of considerable controversy due to the absence of high-level evidence proving its efficacy. Nonetheless, the preponderance of available data suggests that radiation therapy likely improves local control and, in some settings, may favorably impact resectability and survival. These outcome observations coupled with the lower doses (45-54 Gy) and normal tissue displacement characteristic of preoperative radiation therapy leads us to favor preoperative radiotherapy followed by oncologic resection for most retroperitoneal sarcomas. This strategy appears to provide the highest chance of safe and successful delivery of multimodal therapy, which can otherwise be hindered by postoperative complications as a result of technically challenging surgery and normal tissue radiation dose tolerances. Dose-escalation and selective integrative boosts to "at-risk" margins are attractive strategies that merit, and arguably require, further clinical evaluation. We believe that postoperative radiotherapy should be reserved for very high-risk cases and should be treated to a dose of ≥60 Gy respecting normal tissue dose tolerances. An additional approach that we consider in the postoperative setting is close surveillance with consideration of preoperative radiotherapy at recurrence before repeat surgical resection. Highly conformal radiotherapy techniques, such as IMRT with image guidance, should be employed to minimize dose to normal tissues and thereby allow delivery of efficacious radiation doses. If feasible, referral to a treatment facility with proton beam therapy should be discussed with the patient, especially if normal tissue dose constraints cannot be met using IMRT/IGRT. Participation in prospective studies should be highly encouraged.
Conflict of interest statement
Pranshu Mohindra reports no conflicts of interest.
Heather B. Neuman reports no conflicts of interest.
Kevin R. Kozak reports no conflicts of interest.
Figures

Similar articles
-
Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas.Ann Surg Oncol. 2010 Jun;17(6):1515-29. doi: 10.1245/s10434-010-0935-1. Epub 2010 Feb 12. Ann Surg Oncol. 2010. PMID: 20151216 Free PMC article.
-
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience.Radiat Oncol. 2017 Dec 8;12(1):198. doi: 10.1186/s13014-017-0920-y. Radiat Oncol. 2017. PMID: 29216884 Free PMC article. Clinical Trial.
-
Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma.Eur J Surg Oncol. 2020 May;46(5):905-913. doi: 10.1016/j.ejso.2019.12.014. Epub 2019 Dec 17. Eur J Surg Oncol. 2020. PMID: 31892479
-
The role of standard and novel radiotherapy approaches in management of retroperitoneal sarcomas.Eur J Surg Oncol. 2023 Jun;49(6):1111-1114. doi: 10.1016/j.ejso.2022.08.029. Epub 2022 Aug 29. Eur J Surg Oncol. 2023. PMID: 36115783 Review.
-
Role of radiation therapy in retroperitoneal sarcomas.Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4. Oncology (Williston Park). 1996. PMID: 8985970 Review.
Cited by
-
Retroperitoneal soft-tissue sarcomas: Radiotherapy experience from a tertiary cancer center and review of current evidence.Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):643-655. doi: 10.1016/j.rpor.2020.05.006. Epub 2020 Jun 9. Rep Pract Oncol Radiother. 2020. PMID: 32565743 Free PMC article.
-
Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative.J Surg Oncol. 2019 Dec;120(7):1227-1234. doi: 10.1002/jso.25694. Epub 2019 Sep 4. J Surg Oncol. 2019. PMID: 31486096 Free PMC article.
-
Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma.Indian J Surg. 2018 Apr;80(2):154-162. doi: 10.1007/s12262-018-1722-7. Epub 2018 Jan 31. Indian J Surg. 2018. PMID: 29915482 Free PMC article.
-
Retroperitoneal liposarcoma: current insights in diagnosis and treatment.Front Surg. 2015 Feb 10;2:4. doi: 10.3389/fsurg.2015.00004. eCollection 2015. Front Surg. 2015. PMID: 25713799 Free PMC article. Review.
-
Efficacy of surgery in the management of multiple recurrences of retroperitoneal dedifferentiated liposarcoma.World J Surg Oncol. 2024 Oct 5;22(1):265. doi: 10.1186/s12957-024-03552-w. World J Surg Oncol. 2024. PMID: 39369260 Free PMC article.
References
-
- Gilbeau L, Kantor G, Stoeckle E, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65(3):137–43. - PubMed
-
- Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. Cancer Control. 2011;18(3):177–87. - PubMed
-
- Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg. 2007;94(2):145–61. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous